Novogene(SH:688315)2026-02-26 10:40Financial Performance - Total revenue for 2025 reached RMB 2,209.64 million, a year-on-year increase of 4.66%[3] - Net profit attributable to shareholders was RMB 166.11 million, a decrease of 15.59% compared to the previous year[3] - Net profit excluding non-recurring gains and losses was RMB 128.49 million, down 24.75% year-on-year[3] - Basic earnings per share decreased to RMB 0.41, down 14.58% from RMB 0.48[3] Assets and Equity - Total assets at the end of the reporting period were RMB 3,982.45 million, an increase of 9.50% from the end of 2024[4] - Shareholders' equity attributable to the parent company was RMB 2,647.53 million, up 6.33% from the previous year[4] Research and Development - The company increased R&D investment, focusing on AI-enabled research and cutting-edge solutions in single-cell and spatial multi-omics[6] Management and Strategy - Management efficiency improvements led to a reduction in management expense ratio, with resources redirected towards global market expansion[7] - The company aims to build sustainable profitability by investing in advanced technologies to meet customer needs[7] Reporting Accuracy - There are no significant uncertainties affecting the accuracy of the performance report[8]